Ruth Kallay, Reena H Doshi, Pierre Muhoza, Mary J Choi, Anaïs Legand, Emma Aberle-Grasse, Aminata Bagayoko, Terri B Hyde, Pierre Formenty, Alejandro Costa
Ebola virus disease (Ebola) is a rare but severe illness in humans, with an average case fatality rate of approximately 50%. Two licensed vaccines are currently available against Orthoebolavirus zairense, the virus that causes Ebola: the 1-dose rVSVΔG-ZEBOV-GP (ERVEBO [Merck]) and the 2-dose regimen of Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea [Johnson & Johnson]). The Strategic Advisory Group of Experts on Immunization recommends the use of 1-dose ERVEBO during Ebola outbreaks, and in 2021, a global stockpile of ERVEBO was established to ensure equitable, timely, and targeted access to vaccine doses for future Ebola outbreaks...
April 25, 2024: MMWR. Morbidity and Mortality Weekly Report